© 2022 MJH Life Sciences and Cancer Network. All rights reserved.
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
A panel of experts review data from recent conferences and discuss core challenges in the treatment of patients with HER2+ metastatic breast cancer.
November 16th 2021
Panelists provide an overview of the treatment landscape for patients with HER2-positive metastatic breast cancer.
A panel of experts reviews clinical trial data in recurrent HER2-positive metastatic breast cancer and discusses impacts on treatment selection.
November 23rd 2021
Fielding questions from a live audience, experts discuss the lack of biomarkers in HER2+ metastatic breast cancer and how one might address progression of bone disease.
Using a patient case to center their discussion, the panel reviews frontline treatment options for HER2+ metastatic breast cancer and the rationale behind selection.
November 30th 2021
Moving to optimal treatment approaches in second-line therapy, experts close out a patient case of HER2+ metastatic breast cancer.
In another patient case, panelists break down third-line therapy options for someone with HER2+ metastatic breast cancer and lung disease.
December 8th 2021
Panelists field questions from a live audience regarding the optimal selection of therapy for patients with metastatic breast cancer.
Centering their conversation on a patient case, experts discuss the sequencing and monitoring of therapy in patients with HER2+ metastatic breast cancer.
Experts close out their discussion on the management of HER2+ metastatic breast cancer by highlighting their hopes for future treatment strategies.
December 31st 2021
Experts discussed the changing landscape in treatments for HER2-positive metastatic breast cancer.